Food & Drug Administration (FDA) approved the first GLP-1, exenatide, for treatment of type 2 diabetes
Meals that combine protein, fat, and complex carbohydrates produce a steadier blood sugar response than meals built around a single macronutrient
This is called sudden sensorineural hearing loss (SSNHL)
It induces adipogenic effects, leading to early weight gain that stabilizes over time, without the organomegaly associated with GH treatment
One study examining the effects of the GLP-1 liraglutide, for example, found that the medication improved insulin sensitivity within two weeks, prior to weight loss, in people who have obesity and prediabetes, but other research has found that GLP-1s only have minimal direct benefits on insulin sensitivity